Home   About this service   Get the news  
+32 2 743 34 03

 Belgium  Other Countries
Page : 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 - ...
UCB [BE0003739530/UCB]   

UCB : UCB Media Room: First Three Months Interim Report 2018

UCB First Three Months Interim Report 2018:UCB tracking well towards full year financial outlookBrussels Belgium, 25 April 2018 – 18:00 CEST – regulated information –Revenue reached € 1.07 billion: 5%, 1% CER;adjusted for allergy drug divestiture in 2017: 0%; 4% CERUCB’s main five products reached € 839 million 2%, 8% CERR&D update: Cimzia® available for women with chronic... See more
UCB [BE0003739530/UCB]   

UCB : UCB Media Room: UCB acquire the rights to Proximag en’s Midazolam Nasal Spray

UCB to expand epilepsy portfolio with strategic acquisition of Midazolam Nasal Spray from ProximagenMidazolam Nasal Spray USL261, is a nasally administered investigational midazolam formulation intended as a rescue treatment of acute repetitive seizures ARS in patients with epilepsy, which has completed Phase 3 clinical development and is ready to be filed as a New Drug Application NDA in the... See more
UCB [BE0003739530/UCB]   

UCB : UCB Media Room: Acquisition of Element Genomics

UCB strengthens research capabilities with acquisition of Element Genomics, a Duke University biotech spinoffAcquisition to strengthen UCB’s genomics and epigenomics research platform to identify novel drug targetsBrussels, Belgium – April 05, 2018 – UCB announces the acquisition of Element Genomics, a smallsize biotech spinoff from Duke University, based in Durham, North Carolina USA. The... See more
UCB [BE0003739530/UCB]   

UCB : UCB Media Room: Cimzia 4 year data in PsA

New publication on Cimzia® certolizumab pegol shows psoriatic arthritis patients achieved robust treatment targets and sustained improvements across multiple disease domainsBrussels, Belgium – 3 April, 7:00 CEST – UCB announced today that 4year data on Cimzia® certolizumab pegol in the treatment of psoriatic arthritis PsA, in patients both with and without prior antitumor necrosis factor... See more
UCB [BE0003739530/UCB]   

UCB : UCB Media Room: Acquisition of Own Shares

Acquisition of own sharesBrussels Belgium, 30 March 2018 – 20:10 CEST – regulated informationIn application of article 207 of the Royal Decree executing the Companies Code, UCB SA/NV announces that on 28 March 2018, UCB SA/NV and 16 direct affiliates bought 48 711 and 82 807 UCB shares respectively settlement date 3 April 2018, OTC from an affiliate, at a price of € 66.44 per share, in view... See more